MSToronto2026 – 10th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026
Thursday, October 22. 16:30 – 18:30
- POSTER P929: Impact of Ocrelizumab vs Fingolimod on Immune Function in Pediatric Patients With MS in the OPERETTA 2 Study. See also P930, 931.
- POSTER P1047: No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials
- POSTER P1062: Fenebrutinib Reduces CSF Microglial and Astrocyte Biomarkers Expressed at or Near Chronic Active Rim Lesions in Patients With RMS or PPMS
- POSTER P1145: The Risk of Serious Infections Remained Low in People Living With Relapsing Multiple Sclerosis With up to 8 Years of Ofatumumab Treatment
- POSTER P1195: Follow-Up Results of the DOT-MS Trial: Discontinuation of First-Line Disease-Modifying Therapy in Stable Multiple Sclerosis
- POSTER P1305: Obexelimab Demonstrated Reduction in Disease Activity in Relapsing Multiple Sclerosis: 24-Week Results from the MoonStone Phase 2 Trial. See also P1311.
- POSTER P1323: Efficacy and Safety of Orelabrutinib in Relapsing-Remitting Multiple Sclerosis: 24-Week Results of the 80 mg Dose from a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- POSTER P1412: Trend of Disease-Modifying Therapies In Multiple Sclerosis: A 25-Year Population-Based Canadian Study
- POSTER P1644: Ocrelizumab Maintains Clinical and Safety Outcomes in Older Patients (>55 Years) with Progressive Multiple Sclerosis: 2-Year Results from the CONSONANCE Study
- POSTER P2804: Anti-CD38 monoclonal antibody daratumumab for the treatment of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (DAWN): a multicenter, double-blind, randomized phase 3 clinical trial
Canadian co-authored studies
- POSTER 1376: Cross sectional analysis of serum biomarkers and advanced MRI metrics in the CanProCo multiple sclerosis cohort: associations with white matter microstructure, disease duration, and disability
- POSTER P1951: Anti-Epstein Barr Virus Nuclear Antigen 1 IgG1 Titers and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- POSTER P2061: T2 Lesion Volume as a Prognostic Biomarker for Disability Progression: A Post Hoc Analysis from the Phase 3 HERCULES Trial
- POSTER 2122: International Taskforce Consensus on Optical Coherence Tomography in MOG-IgG-Associated Disease
- POSTER P2444: Comparison of disability and progression independent of relapse activity (PIRA) outcomes in early and late onset multiple sclerosis
- POSTER P2704: What Can Electrophysiology Tell Us About Multiple Sclerosis